// App-Quantinova.ai

FP09.02 : Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort

Researchers

Presenter

  • M.R. Garc�a Campelo

Principal Investigators

  • C. Zhou

  • S. Ramalingam

  • H. Lin

  • T. Kim

  • D. Nguyen

  • E. Goodman

  • K. Le

  • M. Mehta

  • S. Popat

  • P. Janne

Medical Centers

  • Seoul National University Hospital, Seoul, Korea

  • Emory University, Atlanta, GA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Shanghai Pulmonary Hospital, Shanghai, China

  • Pacific Shores Medical Group, Long Beach/CA/US

  • Millennium Pharmaceuticals Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited,Cambridge,United States

  • Complejo Hospitalario Universitario A Coruna Hospital Teresa Herrera-Materno InfantIL

  • The Royal Marsden Hospital and the Institute of Cancer Research, London/GB

  • Dana-Farber Cancer Institute, Boston, MA

  • Adventhealth Orlando, Orlando/FL/US

Locations

  • United States

  • China

  • United Kingdom

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • I/II

Study Id's

  • NCT02716116

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved